Samuraciclib (CEC-0942; PPDA-001; CT-7001) is an orally bioavailable and selective CDK7 (Cyclin-dependent kinases) inhibitor with the potential for cancer treatment. It has IC50s of 41 nM and 578 nM for CDK7/CycH/MAT1 and CDK2/cycE1, respectively. Samuraciclib selectively inhibits CDK7, with an IC50 of 40nM; IC50 values for CDK1, CDK2, CDK5 and CDK9 were 45-, 15-, 230- and 30-fold higher. In vitro studies show that a wide range of cancer types are sensitive to CDK7 inhibition with GI50 values ranging between 0.2-0.3 μM.

纯度：≥98%

CAS：1805833-75-3